Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.

Intra-abdominal (IA) fat functionally differs from subcutaneous (SC) adipose tissue, likely contributing to its stronger association with obesity-induced morbidity and to differential response to medications. Drug-induced partial lipodystrophy, like in response to antiretroviral agents, is an extreme manifestation of the different response of different fat depots, with loss of SC but not IA. Investigating depot-specific adipocyte differences is limited by the low accessibility to IA fat and by the heterogenous cell population comprising adipose tissue. Here, we aimed at utilizing immortalized preadipocyte cell lines from IA (epididymal) or SC (inguinal) fat to investigate whether they differentially respond to the HIV protease inhibitor nelfinavir. Preadipocytes were readily amenable to adipogenesis, as evidenced by lipid accumulation, expression of adipose-specific genes, measurable lipolysis, and insulin responsiveness. Leptin secretion was higher by the SC line, consistent with known differences between IA and SC fat. As previously reported, nelfinavir inhibited adipogenesis downstream of C/EBPbeta, but similarly in both cell lines. In contrast, nelfinavir's capacity to diminish insulin signaling, decrease leptin secretion, enhance basal lipolysis, and decrease expression of the lipid droplet-associated protein perilipin occurred more robustly and/or at lower nelfinavir concentrations in the SC line. This was despite similar intracellular concentrations of nelfinavir (23.8 +/- 5.6 and 33.6 +/- 12.2 microg/mg protein for inguinal and epididymal adipocytes, respectively, P = 0.46). The cell lines recapitulated depot-differential effects of nelfinavir observed in differentiated primary preadipocytes and with whole tissue explants. Thus, we report the use of fat depot-specific adipocyte cell lines for unraveling depot-differential responses to a drug causing partial lipodystrophy.

[1]  J. H. Houben-Weerts,et al.  Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes. , 2008, Metabolism: clinical and experimental.

[2]  M. Pirmohamed,et al.  Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes , 2008, AIDS.

[3]  K. Kano,et al.  Establishment of a preadipocyte cell line derived from mature adipocytes of GFP transgenic mice and formation of adipose tissue , 2008, Cell and Tissue Research.

[4]  L. Heilbronn,et al.  Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. , 2008, Current pharmaceutical design.

[5]  M. Christian,et al.  Conditionally immortalized white preadipocytes: a novel adipocyte models⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of three figures. Published, JLR Papers in Press, November 28, 2007. , 2008, Journal of Lipid Research.

[6]  F. Matsumura,et al.  Development of a human adipocyte model derived from human mesenchymal stem cells (hMSC) as a tool for toxicological studies on the action of TCDD , 2008, Biological chemistry.

[7]  M. Uebayasi,et al.  Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid. , 2008, Life sciences.

[8]  R. Blumer Regulation of adiponectin secretion by insulin and amino acids in 3 T 3L 1 adipocytes 2 , 2008 .

[9]  A. Rudich,et al.  Adipose stress-sensing kinases: linking obesity to malfunction , 2007, Trends in Endocrinology & Metabolism.

[10]  Y. Kamei,et al.  Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[11]  A. Rudich,et al.  Regulation of Adipocyte Lipolysis by Degradation of the Perilipin Protein , 2007, Journal of Biological Chemistry.

[12]  G. Frühbeck,et al.  Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? , 2007, Current pharmaceutical design.

[13]  M. Stumvoll,et al.  Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. , 2007, Endocrinology.

[14]  M. Stumvoll,et al.  Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  U. Smith,et al.  Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? , 2007, Diabetologia.

[16]  André Tchemof Visceral adipocytes and the metabolic syndrome , 2007 .

[17]  A. Shirahata,et al.  N-acetylcysteine attenuates TNF-alpha induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. , 2006, Life sciences.

[18]  R. A. Forse,et al.  Fat Depot–Specific Characteristics Are Retained in Strains Derived From Single Human Preadipocytes , 2006, Diabetes.

[19]  Avner Bar Hen,et al.  Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity , 2006, Diabetes.

[20]  Pierre Dupont,et al.  Regional Differences in Adipose Tissue Metabolism in Women , 2006, Diabetes.

[21]  K. Cianflone,et al.  Protease Inhibitor Effects on Triglyceride Synthesis and Adipokine Secretion in Human Omental and Subcutaneous Adipose Tissue , 2005, Antiviral therapy.

[22]  V. Manganiello,et al.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  M. Kalia,et al.  Neurobiological basis of depression: an update. , 2005, Metabolism: clinical and experimental.

[24]  R. Bergman,et al.  Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. , 2005, American journal of physiology. Endocrinology and metabolism.

[25]  G. Bray,et al.  Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. , 2005, Metabolism: clinical and experimental.

[26]  F. Brun-Vézinet,et al.  Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients , 2004, HIV medicine.

[27]  A. Rudich,et al.  Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-ζ , 2004, Diabetologia.

[28]  J. Hrebícek,et al.  Gender differences in tumor necrosis factor alpha and leptin secretion from subcutaneous and visceral fat tissue. , 2004, Physiological research.

[29]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[30]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[31]  H. Lodish,et al.  Standard Isolation of Primary Adipose Cells from Mouse Epididymal Fat Pads Induces Inflammatory Mediators and Down-regulates Adipocyte Genes* , 2003, Journal of Biological Chemistry.

[32]  R. Garg,et al.  Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues , 2003, Diabetologia.

[33]  A. Carr HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management , 2003, AIDS.

[34]  A. Rudich,et al.  Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors , 2003, AIDS.

[35]  C. Tinelli,et al.  Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy. , 2003, AIDS.

[36]  C. Montague,et al.  Adipose depot‐specific effects of PPARγ agonists: a consequence of differential expression of PPARγ in adipose tissue depots? , 2002 .

[37]  D. Giannella‐Neto,et al.  Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[38]  M. Fasshauer,et al.  Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  K. Kristiansen,et al.  A Proteomic Approach for Identification of Secreted Proteins during the Differentiation of 3T3-L1 Preadipocytes to Adipocytes* , 2002, Molecular & Cellular Proteomics.

[40]  P. Reiss,et al.  Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways , 2001, AIDS.

[41]  E. Furfine,et al.  Metabolic complications associated with antiretroviral therapy. , 2001, Antiviral research.

[42]  A. Telenti,et al.  Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Intrapatient Variability , 2001, Therapeutic drug monitoring.

[43]  I. Harman-boehm,et al.  The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. , 2001, Diabetes.

[44]  C. Vigouroux,et al.  The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. , 2001, Diabetes.

[45]  A. Rudich,et al.  Distinct long-term regulation of glycerol and non-esterified fatty acid release by insulin and TNF-α in 3T3-L1 adipocytes , 2001, Diabetologia.

[46]  R. D'Agostino,et al.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  C. Flexner,et al.  Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* , 2000, The Journal of Biological Chemistry.

[48]  J. Klein,et al.  Essential Role of Insulin Receptor Substrate-2 in Insulin Stimulation of Glut4 Translocation and Glucose Uptake in Brown Adipocytes* , 2000, The Journal of Biological Chemistry.

[49]  P. Hruz,et al.  The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.

[50]  J. Klein,et al.  Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. , 2000, Molecular endocrinology.

[51]  R. Maserati,et al.  Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. , 2000, The Journal of antimicrobial chemotherapy.

[52]  J. Klein,et al.  β3-Adrenergic Stimulation Differentially Inhibits Insulin Signaling and Decreases Insulin-induced Glucose Uptake in Brown Adipocytes* , 1999, The Journal of Biological Chemistry.

[53]  T. Saruta,et al.  Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. , 1999, Metabolism: clinical and experimental.

[54]  N. Tajima,et al.  Effect of troglitazone on body fat distribution in type 2 diabetic patients. , 1999, Diabetes care.

[55]  A. Rudich,et al.  Oxidative Stress Disrupts Insulin-induced Cellular Redistribution of Insulin Receptor Substrate-1 and Phosphatidylinositol 3-Kinase in 3T3-L1 Adipocytes , 1999, The Journal of Biological Chemistry.

[56]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[57]  A. Rudich,et al.  Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. , 1998, Diabetes.

[58]  S. O’Rahilly,et al.  Depot-related gene expression in human subcutaneous and omental adipocytes. , 1998, Diabetes.

[59]  M. Digirolamo,et al.  Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[60]  Johan Auwerx,et al.  Depot-Specific Differences in Adipose Tissue Gene Expression in Lean and Obese Subjects , 1998, Diabetes.

[61]  A. Rudich,et al.  Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. , 1997, The American journal of physiology.

[62]  O. MacDougald,et al.  Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Yasuhiro Watanabe,et al.  Wortmannin, a specific phosphatidylinositol 3-kinase inhibitor, inhibits adipocytic differentiation of 3T3-L1 cells. , 1995, Biochemical and biophysical research communications.

[64]  P. Valet,et al.  Molecular mechanisms underlying regional variations of catecholamine-induced lipolysis in rat adipocytes. , 1995, The American journal of physiology.

[65]  C. Russell,et al.  Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. , 1993, The Journal of clinical investigation.

[66]  J. Pessin,et al.  Regulation of the GLUT4/muscle-fat glucose transporter mRNA in adipose tissue of insulin-deficient diabetic rats. , 1993, The Journal of biological chemistry.

[67]  V. Cherington,et al.  Separation of simian virus 40 large-T-antigen-transforming and origin-binding functions from the ability to block differentiation , 1988, Molecular and cellular biology.